Effects of Very Low Dose Oral Anticoagulation on Thromboembolism and Bleeding Events in Patients With Mechanical Heart Valve Replacement
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- 入组人数
- 1,571
- 试验地点
- 1
- 主要终点
- Thromboembolic events, Bleeding events, Survival rates
研究概览
简要总结
We aim to investiagte whether very low dose self management of oral anticoagulation is superior to low dose oral anticoagulation in order to prevent bleeding events in patients undergoing mechanuical heart valve replacement.
详细描述
In mechanical heart valve recipients, self-management of oral anticoagulation can reduce the risk of developing thromboembolic events and improves long-term survival compared with international normalized ratio (INR) control by a general practitioner. Low-dose INR self-management (INR values of 1.8.-2.8 for aortic valve recipients and 2.5 - 3.5 for mitral or double valve recipients) does not increase the risk of thromboembolic events compared to conventional dose INR self-management. Even in patients with a low INR target range, however, the risk of bleeding events is still higher than the risk of thromboembolism. We therefore perform a prospective, randomized trial in 1,800 patients with mechanical heart valve replacement. During the first six postoperative months, low dose INR self-management will be performed by all patients (INR measurement once a week). Thereafter, 600 patients will continue with this treatment regimen, whereas the other 1,200 patients with perform very low dose oral anticoagulation. Out of these 1,200 patients, 600 will perform INR measurement once a week and 600 patients will perform INR measurement twice a week. Patients are followed up for 24 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 85 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Mechanical heart valve recipients
排除标准
- •Contra-indication to phenprocoumon
- •Ulcerous disease with bleeding tendency,
- •Hypo- or hypercoagulability
- •Missing informed consent
研究组 & 干预措施
A
Low dose oral anticoagulation, INR self-management once a week
干预措施: phenprocoumon (Drug)
B
very low dose oral anticoagulation, INR self-management once a week
干预措施: phenprocoumon (Drug)
C
very low dose oral anticoagulation, INR self-management twice a week
干预措施: phenprocoumon (Drug)
结局指标
主要结局
Thromboembolic events, Bleeding events, Survival rates
时间窗: 2 years
次要结局
- INR values, Percent of INR values in the target range(2 years)
